InvestorsObserver
×
News Home

Should You Buy 111 Inc - ADR (YI) in Pharmaceutical Retailers Industry?

Friday, August 25, 2023 02:03 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy 111 Inc - ADR (YI) in Pharmaceutical Retailers Industry?

111 Inc - ADR (YI) is near the top in its industry group according to InvestorsObserver. YI gets an overall rating of 45. That means it scores higher than 45 percent of stocks. 111 Inc - ADR gets a 80 rank in the Pharmaceutical Retailers industry. Pharmaceutical Retailers is number 118 out of 148 industries.

Overall Score - 45
YI has an Overall Score of 45. Find out what this means to you and get the rest of the rankings on YI!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 45 means the stock is more attractive than 45 percent of stocks.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With 111 Inc - ADR Stock Today?

111 Inc - ADR (YI) stock is lower by -1.79% while the S&P 500 is up 0.31% as of 1:55 PM on Friday, Aug 25. YI has fallen -$0.05 from the previous closing price of $2.79 on volume of 38,363 shares. Over the past year the S&P 500 is higher by 4.54% while YI is up 1.11%. YI lost -$0.56 per share the over the last 12 months. Click Here to get the full Stock Report for 111 Inc - ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App